SCHEMBL135264

SCHEMBL135264

COc1ccc(CO)c(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.59
ESR1 P03372 1/20 0.57
CYP19A1 P11511 1/20 0.57
ESR2 Q92731 1/20 0.57
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 3/20 0.48
TRIM24 O15164 1/20 0.48
TYR P14679 1/20 0.48
TRIM33 Q9UPN9 1/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51705 0.85 POLB (0.61) POLBESR1CYP19A1ESR2NPC1
SCHEMBL27297772 0.84 POLB (0.65) POLBESR1CYP19A1ESR2NPC1
SCHEMBL1638977 0.83 GAA (0.52) POLBNPC1RAB9AALDH1A1KDM4E
SCHEMBL2045876 0.83 POLB (0.64) POLBESR1CYP19A1ESR2NPC1
SCHEMBL2061056 0.83 KDM4E (0.50) POLBESR1CYP19A1ESR2ALDH1A1
SCHEMBL639120 0.82 POLB (0.57) POLBESR1CYP19A1ESR2NPC1
SCHEMBL3210936 0.82 POLB (0.57) POLBESR1CYP19A1ESR2NPC1
SCHEMBL22284798 0.82 POLB (0.57) POLBESR1CYP19A1ESR2NPC1
SCHEMBL639119 0.82 POLB (0.57) POLBESR1CYP19A1ESR2NPC1
SCHEMBL2290549 0.82 KDM4E (0.46) POLBESR1CYP19A1ESR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664330-B2 Reactive hot melt adhesive with improved hydrolysis resistance Henkel US IP LLC (US) 2014-03-04 US claimed
US-7037402-B2 Reactive hot melt adhesive with non-polymeric aromatic difunctionals NATIONAL STARCH & CHEMICAL INVESTMENT HOLDING CORPORATION (US) 2006-05-02 US claimed
WO-2004035706-A1 REACTIVE HOT MELT ADHESIVE WITH NON-POLYMERIC AROMATIC DIFUNCTIONALS NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING C ORPORATION (US) 2004-04-29 WO claimed
US-20040072952-A1 Reactive hot melt adhesive with non-polymeric aromatic difunctionals HENKEL AG & CO. KGAA (DE) 2004-04-15 US claimed
US-20230341775-A1 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-10-26 US disclosed
CN-113816985-B Twin monomer containing cationic polymerizable group and preparation method and application thereof 同济大学 2022-11-11 CN disclosed
CN-113816985-A Twin monomer containing cationic polymerizable group and preparation method and application thereof 同济大学 2021-12-21 CN disclosed
CN-107011131-B Aromatic compound containing branched chain 味之素株式会社 2020-11-10 CN disclosed
CN-107011132-B Aromatic compound containing branched chain 味之素株式会社 2020-11-10 CN disclosed
EP-2612845-B1 AROMATIC COMPOUND CONTAINING SPECIFIC BRANCH AJINOMOTO KK (JP) 2020-08-05 EP disclosed
US-10711033-B2 Branched chain-containing aromatic compound AJINOMOTO CO., INC. (JP) 2020-07-14 US disclosed
CN-106220482-B Aromatic compound containing branched chain 味之素株式会社 2020-01-07 CN disclosed
CN-1468102-A Modified prodrug forms of ap/amp ά�¶�ҩƷ��˾ 2004-01-14 CN disclosed
EP-1335726-A1 MODIFIED PRODRUG FORMS OF AP/AMP Vion Pharmaceuticals, Inc. (US) 2003-08-20 EP disclosed
US-20020188011-A1 Antiviral agents and methods of treating viral infections NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-12-12 US disclosed
WO-2002085358-A2 ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS VION PHARMACEUTICALS, INC. (US) 2002-10-31 WO disclosed
US-6458816-B1 ANTICANCER AGENTS VION PHARMACEUTICALS, INC. 2002-10-01 US disclosed
US-20020119955-A1 Modified prodrug forms of AP/AMP NANOTHERAPEUTICS, INC. 2002-08-29 US disclosed
WO-2002030424-A1 MODIFIED PRODRUG FORMS OF AP/AMP VION PHARMACEUTICALS, INC. (US) 2002-04-18 WO disclosed
US-4025553-A Production of o-hydroxybenzyl alcohols SHIONOGI & CO., LTD. (JA) 1977-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188011-A1 Antiviral agents and methods of treating viral infections AMPD3, AMPD2, MTAP POLB 960/4885ESR1 4822/4885CYP19A1 4648/4885
US-10711033-B2 Branched chain-containing aromatic compound VIP, IAPP, BCAT1 POLB 3426/4885ESR1 3642/4885CYP19A1 1967/4885
US-20020119955-A1 Modified prodrug forms of AP/AMP AP3B1, AP3D1, AP3M1 POLB 1211/4885ESR1 2480/4885CYP19A1 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.